These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16804923)

  • 1. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.
    Silver RT
    Cancer; 2006 Aug; 107(3):451-8. PubMed ID: 16804923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Alpha interferon in the therapy of polycythemia vera].
    Castello G; Lerza R; Cavallini D; Ballarino P; Cerruti A; Bogliolo G; Pannacciulli I
    Recenti Prog Med; 1996 Jan; 87(1):7-11. PubMed ID: 8711255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia.
    Elliott MA; Tefferi A
    Semin Thromb Hemost; 1997; 23(5):463-72. PubMed ID: 9387205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous erythroid colony assay in patients with polycythemia vera and its clinical significance.
    Bai J; Shao ZH; Liu H; Shi J; He GS; Cao YR; Cui ZZ; Wu YH; Sun J; Tian Z; Jia HR; Qian LS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 May; 117(5):668-72. PubMed ID: 15161531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate.
    Silver RT
    Curr Hematol Rep; 2005 May; 4(3):235-7. PubMed ID: 15865878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera.
    Foa P; Massaro P; Caldiera S; LaTargia ML; Iurlo A; Clerici C; Fornier M; Bertoni F; Maiolo AT
    Eur J Haematol; 1998 May; 60(5):273-7. PubMed ID: 9654155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modern treatment strategies in polycythemia vera.
    Gilbert HS
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):26-9. PubMed ID: 12682879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based management of polycythemia vera.
    Barbui T; Finazzi G
    Best Pract Res Clin Haematol; 2006; 19(3):483-93. PubMed ID: 16781485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
    Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Papaemmanuil E; Salama M; Singer-Weinberg R; Rampal R; Goldberg JD; Barbui T; Mesa R; Dueck AC; Hoffman R
    Blood; 2019 Oct; 134(18):1498-1509. PubMed ID: 31515250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of polycythemia. I--Using radiophosphorus with or without treatment in 483 patients over 65 years of age].
    Najean Y; Rain JD; Goguel A; Grange MJ; Vigneron N; Dupuy E; Mougeot-Martin M
    Ann Med Interne (Paris); 1998 Mar; 149(2):87-93. PubMed ID: 11490530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa.
    Finelli C; Gugliotta L; Gamberi B; Vianelli N; Visani G; Tura S
    Am J Hematol; 1993 Aug; 43(4):316-8. PubMed ID: 8372816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.
    Gilbert HS
    Cancer; 1998 Sep; 83(6):1205-13. PubMed ID: 9740087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of polycythemia vera.
    Silver RT
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):437-42. PubMed ID: 16810620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of recombinant interferon-alpha in polycythaemia vera.
    Oztürk A; Günay A; Uskent N
    Acta Haematol; 1998; 99(2):89-91. PubMed ID: 9554456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and therapy of polycythemia vera.
    Lengfelder E; Merx K; Hehlmann R
    Semin Thromb Hemost; 2006 Apr; 32(3):267-75. PubMed ID: 16673281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interferon alpha in the treatment of polycythemia vera in a 13-year-old girl].
    Ołpiński M; Jakieła T; Korczowski R
    Pediatr Pol; 1996 Aug; 71(8):705-7. PubMed ID: 8927476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T; Finazzi G
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.